Wednesday, August 31, 2022 6:16:31 PM
OTLC
Oncotelic Therapeutics Inc (QB)
0.08077
0.00027 (0.34%)
Volume: 563,673
Day Range: 0.08 - 0.082
Bid: 0.0681
Ask: 0.09
Last Trade Time: 3:44:59 PM EDT
Total Trades: 29
OTLC Detailed Quote
Oncotelic Therapeutics Inc (QB)
0.08077
0.00027 (0.34%)
Volume: 563,673
Day Range: 0.08 - 0.082
Bid: 0.0681
Ask: 0.09
Last Trade Time: 3:44:59 PM EDT
Total Trades: 29
OTLC Detailed Quote
Recent OTLC News
- Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026 • GlobeNewswire Inc. • 05/28/2026 12:30:00 PM
- Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress • GlobeNewswire Inc. • 05/15/2026 01:00:00 PM
- NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 09:16:22 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform • GlobeNewswire Inc. • 05/14/2026 12:30:00 PM
- Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus • GlobeNewswire Inc. • 05/13/2026 02:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies • GlobeNewswire Inc. • 05/12/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease • GlobeNewswire Inc. • 05/06/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:21:45 PM
- Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways • GlobeNewswire Inc. • 04/24/2026 12:30:00 PM
- Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy • GlobeNewswire Inc. • 04/24/2026 12:00:00 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • InvestorsHub NewsWire • 04/20/2026 01:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 01:00:28 PM
- Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress • GlobeNewswire Inc. • 04/16/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:31:31 PM
- Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space • GlobeNewswire Inc. • 04/10/2026 12:30:00 PM
